Merck made a formal request for Emergency Use Authorization from the FDA Monday for its COVID-19 pill treatment, known as molnupiravir. Merck (MRK) said Monday it has submitted a formal ...

An FDA advisory committee voted by 13 to 10 to recommend emergency-use authorisation for Merck & Co and Ridgeback's oral antiviral molnupiravir for mild-to-moderate COVID-19, saying it would be ...

A new study released Monday said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally ...

While Merck and its partner Ridgeback Biotherapeutics were the first to submit their COVID-19 pill to the FDA, rival drugmaker Pfizer is close behind with its own pill under review.

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

The first-ever COVID-19 pill could be available before the end of the year. This week, Merck and Ridgeback Biotherapeutics asked the Food and Drug Administration (FDA) to authorize their antiviral ...

The Food and Drug Administration approved the latest Covid vaccines yesterday ... Columbia that bears the Vagelos family name. A former Merck CEO, Roy Vagelos is the child of Greek immigrants ...

WASHINGTON--Drugmaker Merck asked U.S. regulators Monday ... first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...